TEK and acute myeloid leukemia: Angiopoietin 1 is a regulator of angiogenesis without any prognostic impact by itself in human AML, whereas extracellular levels (serum, bone marrow plasma) of the potential Tie2 antagonist Angiopoietin 2 has an adverse prognostic impact in human AML [62-64].